46 related articles for article (PubMed ID: 9272733)
1. In vitro conversion of irinotecan to SN-38 in human plasma.
Shingyoji M; Takiguchi Y; Watanabe-Uruma R; Asaka-Amano Y; Matsubara H; Kurosu K; Kasahara Y; Tanabe N; Tatsumi K; Kuriyama T
Cancer Sci; 2004 Jun; 95(6):537-40. PubMed ID: 15182436
[TBL] [Abstract][Full Text] [Related]
2. Evaluation on the Metabolic Activity of Two Carboxylesterase Isozymes in Mouse Liver Microsomes by a LC-MS/MS Method.
Lan L; Li M; Xu Y; Ren X; Zhang C
J Chromatogr Sci; 2023 Dec; 61(10):980-987. PubMed ID: 36585777
[TBL] [Abstract][Full Text] [Related]
3. Elucidation of Carboxylesterase Mediated Pharmacokinetic Interactions between Irinotecan and Oroxylin A in Rats via Physiologically Based Pharmacokinetic Modeling.
Zhang J; Zhang Y; Lai YS; Song Q; Xiao M; Ji X; Yan X; Zuo Z
Pharm Res; 2023 Nov; 40(11):2627-2638. PubMed ID: 37667147
[TBL] [Abstract][Full Text] [Related]
4. Tight-Binding Small-Molecule Carboxylesterase 2 Inhibitors Reduce Intracellular Irinotecan Activation.
Kailass K; Casalena D; Jenane L; McEdwards G; Auld DS; Sadovski O; Kaye EG; Hudson E; Nettleton D; Currie MA; Beharry AA
J Med Chem; 2024 Feb; 67(3):2019-2030. PubMed ID: 38265364
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel carboxylesterase 2 inhibitors for the treatment of delayed diarrhea and ulcerative colitis.
Cao Z; Liu Y; Chen S; Wang W; Yang Z; Chen Y; Jiao S; Huang W; Chen L; Sun L; Li Z; Zhang L
Biochem Pharmacol; 2023 Sep; 215():115742. PubMed ID: 37567318
[TBL] [Abstract][Full Text] [Related]
6. Binding Performance of Human Intravenous Immunoglobulin and 20(
Liu YC; Li YY; Yao XJ; Qi HL; Wei XX; Liu JN
Molecules; 2018 Sep; 23(9):. PubMed ID: 30231526
[TBL] [Abstract][Full Text] [Related]
7. In Silico Study of Camptothecin-Based Pro-Drugs Binding to Human Carboxylesterase 2.
Beierlein F; Horn AHC; Sticht H; Mokhir A; Imhof P
Biomolecules; 2024 Jan; 14(2):. PubMed ID: 38397391
[TBL] [Abstract][Full Text] [Related]
8. New bysspectin A derivatives as potent inhibitors of human carboxylesterase 2A.
Li W; Zhang Y; Wu Y; Zhu G; Liu X; Song Y; Ma B; Lin S; Ge G; Jiao X; Xie P
Eur J Med Chem; 2023 Nov; 259():115708. PubMed ID: 37544184
[TBL] [Abstract][Full Text] [Related]
9. Bioorthogonal Uncaging of the Active Metabolite of Irinotecan by Palladium-Functionalized Microdevices.
Adam C; Pérez-López AM; Hamilton L; Rubio-Ruiz B; Bray TL; Sieger D; Brennan PM; Unciti-Broceta A
Chemistry; 2018 Nov; 24(63):16783-16790. PubMed ID: 30187973
[TBL] [Abstract][Full Text] [Related]
10. Single protein encapsulated SN38 for tumor-targeting treatment.
Yu C; Huang F; Wang K; Liu M; Chow WA; Ling X; Li F; Causey JL; Huang X; Cook-Wiens G; Cui X
J Transl Med; 2023 Dec; 21(1):897. PubMed ID: 38072965
[TBL] [Abstract][Full Text] [Related]
11. CPT11 with P-glycoprotein/CYP 3A4 dual-function inhibitor by self-nanoemulsifying nanoemulsion combined with gastroretentive technology to enhance the oral bioavailability and therapeutic efficacy against pancreatic adenocarcinomas.
Chen LC; Cheng WJ; Lin SY; Hung MT; Sheu MT; Lin HL; Hsieh CM
Drug Deliv; 2021 Dec; 28(1):2205-2217. PubMed ID: 34662257
[TBL] [Abstract][Full Text] [Related]
12. Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.
de Man FM; Goey AKL; van Schaik RHN; Mathijssen RHJ; Bins S
Clin Pharmacokinet; 2018 Oct; 57(10):1229-1254. PubMed ID: 29520731
[TBL] [Abstract][Full Text] [Related]
13. Age-Dependent Absolute Abundance of Hepatic Carboxylesterases (CES1 and CES2) by LC-MS/MS Proteomics: Application to PBPK Modeling of Oseltamivir In Vivo Pharmacokinetics in Infants.
Boberg M; Vrana M; Mehrotra A; Pearce RE; Gaedigk A; Bhatt DK; Leeder JS; Prasad B
Drug Metab Dispos; 2017 Feb; 45(2):216-223. PubMed ID: 27895113
[TBL] [Abstract][Full Text] [Related]
14. The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and beta-glucuronidase in human colorectal tumours.
Tobin P; Clarke S; Seale JP; Lee S; Solomon M; Aulds S; Crawford M; Gallagher J; Eyers T; Rivory L
Br J Clin Pharmacol; 2006 Jul; 62(1):122-9. PubMed ID: 16842384
[TBL] [Abstract][Full Text] [Related]
15. Human multidrug resistance associated protein 4 confers resistance to camptothecins.
Tian Q; Zhang J; Tan TM; Chan E; Duan W; Chan SY; Boelsterli UA; Ho PC; Yang H; Bian JS; Huang M; Zhu YZ; Xiong W; Li X; Zhou S
Pharm Res; 2005 Nov; 22(11):1837-53. PubMed ID: 16132345
[TBL] [Abstract][Full Text] [Related]
16. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.
Schoemaker NE; Kuppens IE; Moiseyenko V; Glimelius B; Kjaer M; Starkhammer H; Richel DJ; Smaaland R; Bertelsen K; Poulsen JP; Voznyi E; Norum J; Fennelly D; Tveit KM; Garin A; Gruia G; Mourier A; Sibaud D; Lefebvre P; Beijnen JH; Schellens JH; ten Bokkel Huinink WW
Br J Cancer; 2004 Oct; 91(8):1434-41. PubMed ID: 15381932
[TBL] [Abstract][Full Text] [Related]
17. Practical treatment guide for dose individualisation in cancer chemotherapy.
Canal P; Chatelut E; Guichard S
Drugs; 1998 Dec; 56(6):1019-38. PubMed ID: 9878990
[TBL] [Abstract][Full Text] [Related]
18. The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms.
Haaz MC; Rivory LP; Riché C; Robert J
Naunyn Schmiedebergs Arch Pharmacol; 1997 Aug; 356(2):257-62. PubMed ID: 9272733
[TBL] [Abstract][Full Text] [Related]
19. Bioactivation of the anticancer agent CPT-11 to SN-38 by human hepatic microsomal carboxylesterases and the in vitro assessment of potential drug interactions.
Slatter JG; Su P; Sams JP; Schaaf LJ; Wienkers LC
Drug Metab Dispos; 1997 Oct; 25(10):1157-64. PubMed ID: 9321519
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
